Related Experiment Videos
[Experimental study on levamisole modulation of antitumor immunity--1]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1982
Summary
Levamisole (LMS) demonstrates antitumor effects by enhancing immune cell activity against rat mammary tumors. Optimal dosing and timing are crucial, as improper use can impede tumor suppression and interfere with other treatments.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Context:
- Investigating immunomodulatory agents for cancer therapy.
- Utilizing the metastasizing rat's mammary tumor (MRMT-1) model for preclinical studies.
- Assessing the impact of levamisole (LMS) on antitumor immunity.
Purpose:
- Determine the optimal dose and administration timing of LMS for antitumor effects.
- Elucidate the immunological mechanisms underlying LMS-mediated tumor modulation.
- Evaluate the interaction between LMS and splenectomy in tumor suppression.
Summary:
- Optimal LMS administration (2.5 mg/kg every other day) suppressed MRMT-1 tumor growth, while higher doses promoted progression.
- Early LMS administration (day 2 post-inoculation) was most effective; late administration (day 14) showed transient tumor progression.
- LMS enhances peripheral lymphocyte immunocompetency and cytotoxicity but reduces NK cell activity; it also affects spleen and thymus cell functions.
Impact:
- Provides insights into optimizing levamisole dosage and treatment schedules for cancer immunotherapy.
- Suggests LMS modulates antitumor immunity through enhanced lymphocyte function and cytotoxicity.
- Highlights potential interactions between LMS and surgical interventions like splenectomy.